Clinical Trial Search

Primary: Number of Participants With Treatment-emergent Serious Adverse Events (SAE). — 0; 0 Participants

Primary: Percent Change From Baseline in Body Weight at Week 26 — -1.76; -8.51; -9.83; -11.80 Percent Change — p=< 0.001

Primary: Migraine Days — 14.267; 14.133; 11.067; 9.867 Days

Primary: Percent Disease Control Rate (DCR) — 33 percentage of participants

Primary: Change in Score in Worst Pain Over the Last Month — -0.5; -5 score on a scale

Primary: Mean Percentage of Perforin+ CD4+ and CD8+ T Cells After Stimulation With M-001 Component Peptides — 1.180; 0.781; 1.090; 0.779 percentage of cells — p=0.53

Primary: Objective Response Rate (ORR) of Pembrolizumab Plus Epacadostat Versus Pembrolizumab Plus Placebo — 32.5; 39.0 percentage of participants — p=0.8000

Primary: Number of Participants With a Complete Response (CR) + Partial Response (PR) — 0; 5; 1; 11 Participants

Primary: RAD001 Response Rate Based on 2D MRI Change From Baseline — 15 participants — p=<0.001

Primary: Change in Plasma IGF-1 From Baseline to Post-Treatment — 19.12; 8.54 ng/mL — p=0.190

Primary: Mean Change of Tissue Factor Bearing Microparticles — 102; -618 microparticles per microliter

Primary: Safety Assessed by Adverse Events, Magnetic Resonance Imaging (MRI), X-ray Imaging, Physical Examination, Neurologic Examination and Vital Signs — 6; 6; 6; 5 Participants

Primary: Change From Baseline in Papule/Pustule Count at Week 16 — -5.00 papules and pustules — p=0.01

Primary: Percent Changes From Baseline to End-of-treatment in Non-HDL Cholesterol, HDL Cholesterol, and Triglycerides by LCP-AtorFen Versus Atorvastatin Monotherapy — -44.8…

Primary: Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains — NA; NA; NA; NA titers (1/dilution)